Across TCGA pan-cancer cohorts, TMEM184B RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated TMEM184B data layer compared with 2 for mutation status and 4 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TMEM184B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM184B expression acts as an unfavorable survival marker, although some lineages such as ESCA and SCLC show a favorable association.
ACC, UVM, and MESO are the cancer types where TMEM184B RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.